CSS LLC’s Rubius Therapeutics, Inc RUBY Stock Holding History

CSS LLC’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-22,200	Closed	-$588K	–	1224
2021 Q1	$588K	Buy	+22,200	New	+$324K	0.02%	551

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CSS LLC's RUBY Position: Q2 2021 in Review

CSS LLC sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2021, closing a stake of 3,500 shares — an estimated $93K sold.

CSS LLC first reported a position in RUBY in Q1 2021 and held it in 1 quarter. The position peaked at $93K in Q1 2021. 108 funds tracked by Wall St. Rank hold RUBY as of Q2 2021.

CSS LLC reported no remaining Rubius Therapeutics, Inc position as of Q2 2021 after selling out during the quarter.
CSS LLC sold 3,500 Rubius Therapeutics, Inc shares in Q2 2021, an estimated $93K.
CSS LLC first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 1 quarter.
CSS LLC's Rubius Therapeutics, Inc position peaked at $93K in Q1 2021.
108 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2021.

Based on CSS LLC's 13F filing for Q2 2021, filed 16 Aug 2021.